Vaxcyte, INC Form 4 insider transactions

Vaxcyte, Inc. director Olivier Brandicourt was granted 1,357 restricted stock units and options to purchase 6,750 shares of common stock.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, sold 9,743 shares of common stock for approximately $46.69 per share under a pre-arranged trading plan.

Vaxcyte's SVP of Finance, Elvia Cowan, reported sales of common stock totaling 11,623 shares and a gift of 1,000 shares to a charitable fund.

Vaxcyte's SVP of Finance, Elvia Cowan, disposed of 482 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, disposed of 1,204 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the disposition of 4,422 shares of common stock through tax withholding and a divorce settlement.

Vaxcyte's President and CFO, Andrew Guggenhime, disposed of 2,890 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte, Inc. CEO Grant Pickering disposed of 7,356 shares of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's SVP of Finance, Elvia Cowan, disposed of common stock to cover tax withholding obligations related to RSU vesting.

Vaxcyte's Chief Technical Operations Officer, Harpreet S. Dhaliwal, reported the surrender of shares to cover tax obligations related to RSU vesting.

Vaxcyte's Chief Operating Officer, Jim Wassil, reported the disposition of shares for tax obligations and a transfer related to a divorce settlement, alongside an acquisition through an employee stock plan.

Vaxcyte's President and CFO, Andrew Guggenhime, reported the surrender of shares to cover tax withholding obligations related to RSU vesting.

Vaxcyte CEO Grant Pickering reported the surrender of shares to cover tax withholding obligations related to RSU vesting, alongside updates to his beneficial ownership.

Vaxcyte's SVP of Finance, Elvia Cowan, reported the acquisition of restricted stock units and stock options as part of her compensation.

Vaxcyte, Inc. Director Olivier Brandicourt has reported the acquisition of 1,148 shares of common stock through restricted stock units and 5,807 stock options, effective June 12, 2025.

Vaxcyte, Inc. Director Halley E. Gilbert reported the acquisition of 3,041 restricted stock units and 15,372 stock options, alongside a transfer of previously held options, as detailed in a recent SEC Form 4 filing.

Vaxcyte, Inc. Director Teri Loxam was granted 3,041 Restricted Stock Units (RSUs) and options to purchase 15,372 shares of common stock, aligning her compensation with company performance.

Vaxcyte, Inc. Director Heath Lukatch was granted 3,041 restricted stock units and options to purchase 15,372 shares of common stock as part of his compensation.

Vaxcyte, Inc. Director John Furey received a grant of 3,041 restricted stock units and 15,372 stock options as part of his compensation.

Vaxcyte, Inc. Director Jacks Lee was granted 3,041 restricted stock units and options to purchase 15,372 shares of common stock on June 12, 2025.

Vaxcyte, Inc. Director Anne S. Drapeau has reported the acquisition of 3,041 shares of common stock through restricted stock units and 15,372 stock options, increasing her beneficial ownership in the company.

Vaxcyte, Inc. Director Carlos V. Paya was granted 3,041 restricted stock units and 15,372 stock options as part of his compensation, aligning his interests with shareholders.

Director Olivier Brandicourt acquired stock options in Vaxcyte, Inc. on May 1, 2025.

Director Heath Lukatch exercised stock options at Vaxcyte, Inc. on April 8, 2025, resulting in changes to his beneficial ownership of company stock.

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., reports exercising stock options and subsequent beneficial ownership of securities.

Vaxcyte's CEO, Grant Pickering, executed stock options at prices of $5.35 and $20.93, altering his beneficial ownership in the company.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Andrew Guggenhime, CFO of Vaxcyte, Inc., reports acquisition and disposal of common stock and stock options.

Elvia Cowan, SVP of Finance at Vaxcyte, Inc., reports the acquisition and disposal of common stock and stock options.

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports acquisition and disposal of common stock and stock options.